NCT00999401View on ClinicalTrials.gov

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 16, 2019

Study Completion Date

August 13, 2019

Conditions
Advanced Solid Tumors
Interventions
DRUG

sapacitabine and seliciclib

sequential or concomitant administration of sapacitabine and seliciclib

Trial Locations (2)

02115

Dana Farber Cancer Institute, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT00999401 - A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter